Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Curis LifesciencesNSE:CURIS +11.71%20 3-Year ROIIC % is 13.64 as of Mar. 2026, which is at its 10-year median of 13.64. GuruFocus rates NSE:CURIS with a GF Score™ of 20/100. The stock has 2 warning signs investors should review. Among 943 Drug Manufacturers companies, Curis Lifesciences ranks better than 64.69% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Curis Lifesciences's 3-Year ROIIC % for the quarter that ended in Mar. 2026 was 13.64%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Curis Lifesciences's 3-Year ROIIC % or its related term are showing as below:
NSE:CURIS's 3-Year ROIIC % is ranked better than 64.69% of 943
companies
in the Drug Manufacturers industry
Industry Median: 3.56
vs NSE:CURIS: 13.64
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Curis Lifesciences 3-Year ROIIC % Related Terms
Curis Lifesciences 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Curis Lifesciences's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curis Lifesciences 3-Year ROIIC % Chart
Curis Lifesciences Annual Data
Trend
Mar23
Mar24
Mar25
Mar26
3-Year ROIIC %
0.00
0.00
0.00
13.64
Curis Lifesciences Semi-Annual Data
Mar23
Mar24
Mar25
Mar26
3-Year ROIIC %
0.00
0.00
0.00
13.64
NSE:CURIS vs ZTS: 3-Year ROIIC % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Curis Lifesciences's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Curis Lifesciences 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Curis Lifesciences's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Curis Lifesciences's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Curis Lifesciences (NSE:CURIS) has a 3-Year ROIIC % of 13.64 as of Mar. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Curis Lifesciences and its competitors. This is near median its historical median of 13.64. Over the past decade, Curis Lifesciences' 3-Year ROIIC % has ranged from 13.64 to 13.64. According to the industry distribution chart, Curis Lifesciences ranks #333 out of 943 companies in the Drug Manufacturers industry, placing it in the top 35.3%.
Is Curis Lifesciences' 3-Year ROIIC % too high?
Curis Lifesciences' current 3-Year ROIIC % of 13.64 is near median its 10-year median of 13.64. Over the past 10 years, this metric has ranged from a low of 13.64 to a high of 13.64. The Drug Manufacturers industry median 3-Year ROIIC % is 3.56. Curis Lifesciences' value of 13.64 is 283.1% above this industry median. Based on the distribution chart, Curis Lifesciences ranks #333 out of 943 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Curis Lifesciences has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Curis Lifesciences' 3-Year ROIIC % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Curis Lifesciences ranks #333 out of 943 companies for 3-Year ROIIC %. This puts Curis Lifesciences in the upper half of its industry. The industry median 3-Year ROIIC % is 3.56. Curis Lifesciences' value of 13.64 is 283.1% above this benchmark. Historically, Curis Lifesciences' own 3-Year ROIIC % has ranged from 13.64 to 13.64 over the past decade. While the company's 10-year median is 13.64 vs. the industry median of 3.56, Curis Lifesciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.56, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Curis Lifesciences's current 3-Year ROIIC % of 13.64 is 283.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Curis Lifesciences and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curis Lifesciences's current 3-Year ROIIC % is 13.64, which is near median its own 10-year median of 13.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curis Lifesciences stock overvalued right now?
Curis Lifesciences (NSE:CURIS) has a current 3-Year ROIIC % of 13.64. The current 3-Year ROIIC % is 13.64, which is near median its 10-year median of 13.64 and 283.1% above the Drug Manufacturers industry median of 3.56. Curis Lifesciences' overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Curis Lifesciences (NSE:CURIS), the current 3-Year ROIIC % is 13.64 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Curis Lifesciences Ltd is in the business of manufacturing of pharmaceutical products. It specializes in the manufacturing of a wide range of pharmaceutical products such as Tablets, Capsules, External Preparations, Oral liquid, and Sterile Ophthalmic Ointments. The company's business verticals are: Loan License manufacturing, Contract Manufacturing, and Direct Export. The company derives revenue from the sale of its pharmaceutical products.
20GF Score
Get the complete analysis for NSE:CURIS
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CURIS has been successfully added to your 
